European Companies Search Engine
EU funding (€15.1M): Biomarker Enterprise to Attack DKD - Sofia ref.: 115974 Hor1 Sept 2016 EU Research and Innovation programme "Horizon"
Overview
Text
Biomarker Enterprise to Attack DKD - Sofia ref.: 115974
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached epidemic dimensions in recent years. Unfortunately, there are no effective means to prevent or cure DKD, the few existing treatments have limited effect and very few alternative therapies have emerged in the past years. Lack of new predictive and prognostic biomarkers for a more accurate patient stratification, limited access to kidney tissue from patients at various stages of DKD as well as novel model systems to better understand the pathogenesis of the disease, are likely reasons for the stagnating development of new treatments. The BEAt-DKD consortium combines outstanding basic and translational researchers in nephropathy, diabetes, kidney model systems, imaging techniques and systems biology, and includes leaders of diabetes and kidney disease-relevant IMI1, FP7 and US consortia, like SUMMIT, KIDNEYCONNECT, Syskid, CPROBE and C-Path, in an unprecedented search for new and better biomarkers for DKD, through a better understanding of the disease. Jointly, the partners have access to vast and very relevant clinical cohorts and trials, state-of-the-art analysis and imaging techniques, novel model systems and the long-standing experience and networks to make this collaboration a success. By involving regulatory agencies throughout the project, BEAt-DKD aims at making the introduction and acceptance of new tools as efficient as possible. The overall goals of BEAt-DKD are (1) to provide a holistic systems medicine view of the pathogenesis of DKD with the aim to identify targetable mechanisms and pathways underlying initiation and progression of DKD, applying a novel sub-classification of diabetes, and (2) to identify and validate biomarkers of disease progression and treatment responses representing first steps towards precision medicine in the management of DKD.
Funded Companies:
| Company name | Funding amount |
| Abbvie Inc. | €0.00 |
| Academisch Ziekenhuis Groningen | €1,942,896 |
| Antaros Medical AB | €16,125.00 |
| €0.00 | |
| Astellas Pharma Europe B.V. | €0.00 |
| €0.00 | |
| BAYER AG | €0.00 |
| €0.00 | |
| Bayer Pharma AG | €0.00 |
| CHU Hopitaux de Bordeaux | €33,087 |
| Eli Lilly and Company Ltd. | €0.00 |
| HELSINGIN YLIOPISTO | €1,001,300 |
| ITA-SUOMEN YLIOPISTO | €200,000 |
| Istituto DI Ricerche Farmacologiche Mario Negri | €150,000 |
| €0.00 | |
| €360,000 | |
| LIPOTYPE | €300,000 |
| Lunds Universitet | €2,509,153 |
| Medizinische Universitaet Wien | €950,000 |
| €930,000 | |
| Novo Nordisk A/S | €0.00 |
| SANOFI-AVENTIS DEUTSCHLAND GmbH | €0.00 |
| SIB SWISS INSTITUTE OF BIOINFORMATICS | €444,000 |
| TURUN YLIOPISTO | €245,001 |
| The Chancellor, Masters and Scholars of the University of Oxford | €5,077.91 |
| €0.00 | |
| €670,656 | |
| €775,192 | |
| UNIVERSITAETSKLINIKUM FREIBURG | €44,083 |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | €1,544,468 |
| €387,500 | |
| €620,000 | |
| €0.00 | |
| €583,883 | |
| University of Dundee | €655,000 |
| University of Hull | €250,000 |
| University of Leeds | €468,515 |
| VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA | €0.00 |
Source: https://cordis.europa.eu/project/id/115974
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Abbvie Inc. - EU funding (€15.1M): Biomarker Enterprise to Attack DKD - Sofia ref.: 115974"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
